Tapimmune Inc’s Price Jumped After Eastern Capital Ltd increased Its Position

May 16, 2018 - By Brian Ramirez

TapImmune, Inc. (NASDAQ:TPIV) Corporate Logo

The increased Interest in Tapimmune Inc was posted by Eastern Capital Ltd

Eastern Capital Ltd filed with SEC a SC 13D/A form about Tapimmune Inc. The form can be accessed here: 000140840818000005.As reported by Eastern Capital Ltd, the filler increased its stake in the stock by 24.53 % for 5,300,002 shares.On May14, 2018 Eastern Capital Ltd holds 38.8% of the stock.

And that’s Why Eastern Capital Ltd Holds Tapimmune Inc

Item 4.Purpose of Transaction

On May 14, 2018, Eastern CapitalLimited entered into a Common Stock Purchase Agreement with the Issuer to purchase 1,300,000 shares of common stock at a priceper share of $2.40.

The Reporting Persons acquiredthe Issuer’s securities for investment purposes.

The Reporting Persons currentlyhave no plans or proposals which relate to or would result in any transaction, event or action enumerated in paragraphs (a) through(j) of Item 4 of Schedule 13D.

CUSIP No. 876033408 Page 6 of 8

Ticker’s shares touched $3.26 during the last trading session after 7.59% change.TapImmune, Inc. is downtrending after having declined 26.26% since May 17, 2017. TPIV has 153,209 volume or 262.58% up from normal. TPIV underperformed by 37.81% the S&P500.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease.The company has $34.64 million market cap. It specializes in the development of immunotherapies targeting women's cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers.Currently it has negative earnings. The company's peptide-or nucleic acid immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid expression systems.

For more TapImmune, Inc. (NASDAQ:TPIV) news brought out briefly go to: Benzinga.com, Prnewswire.com, Prnewswire.com, Prnewswire.com or Prnewswire.com. The titles are as follows: “32 Stocks Moving In Tuesday’s Mid-Day Session” brought out on May 01, 2018, “TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform” on May 16, 2018, “TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference” with a publish date: May 01, 2018, “TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno …” and the last “TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics” with publication date: May 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.